Diabetes Care
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Diabetes Care 31:e17 2008
DOI: 10.2337/dc07-2234
© 2008 by the American Diabetes Association
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Porcellati, F.
Right arrow Articles by Fanelli, C. G.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Porcellati, F.
Right arrow Articles by Fanelli, C. G.
Social Bookmarking
Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Online Letters: Comments and Responses

Comparison of Pharmacokinetics and Dynamics of the Long-Acting Insulin Analogs Glargine and Detemir at Steady State in Type 1 Diabetes: a Double-Blind, Randomized, Crossover Study

Response to Banarer

Francesca Porcellati, MD, Paolo Rossetti, MD, Geremia B. Bolli, MD and Carmine G. Fanelli, MD

From the Department of Internal Medicine, Section of Internal Medicine, Endocrinology and Metabolism, University of Perugia, Perugia, Italy

Address correspondence to Prof. Geremia B. Bolli, Department of Internal Medicine, Endocrinology and Metabolism, University of Perugia, Via E. Dal Pozzo 06126 Perugia, Italy. E-mail: gbolli@unipg.it

The first 20% of the full text of this article appears below.

We thank Dr. Banarer (1) for his appreciation of our work (2) and for the opportunity to discuss his criticism.

The formula we used to describe the insulin activity profile was constructed to emphasize the ability of a basal insulin preparation to maintain plasma glucose at the target value during fasting, which is the clinical target of a basal insulin preparation. Accordingly, the second variable of the formula, plasma glucose concentration, was given greater . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum
Copyright © 2008 by the American Diabetes Association.